Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

"The monthly installments, if taken for 20 years, are approximately Rp1 million. This already includes fire, credit, and life insurance," said Heru. Minister of Home Affairs Muhammad Tito Karnavian ...

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

AKRA is rated "Buy" with a 12-month target price of Rp1,903.85, a ‎20.50% upside from the current price of Rp1,580.00. See more ...